
|Articles|October 1, 2003
Melanoma Activist
Chicago - An orally active small molecule inhibitor of Raf kinase, the first of its class to enter clinical trials, is well tolerated when combined with standard chemotherapy agents, and may have activity against metastatic melanoma, Keith T. Flaherty, M.D., said at the annual meeting of the American Society of Clinical Oncology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
2
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
3
JAK Inhibitors Show Comparable Safety to TNF Antagonists
4
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 1
5


















